A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910